Diagens Biotechnology Pursues Hong Kong IPO Listing
Diagens Biotechnology passed a Hong Kong Stock Exchange listing hearing and posted its prospectus on March 15, with Huatai International as sole sponsor. The Hangzhou firm says its iMedImage foundation model powers AI Autovision, a chromosome karyotyping diagnostic system that achieved 100% sensitivity and specificity for numerical abnormalities in a 1,518-sample trial and gained innovative Class 3 designation for accelerated review. Diagens reported RMB112 million revenue in the first three quarters of 2025.
Key Points
- 1Passed HKEX listing hearing and posted March 15 prospectus; Huatai International serves as sole sponsor
- 2Demonstrated clinical efficacy with 100% sensitivity/specificity for numerical chromosomal abnormalities in 1,518 samples
- 3Plans to license iMedImage foundation model locally, enabling hospitals to train disease-specific imaging models
Scoring Rationale
Official prospectus and robust trial claims increase impact, but reliance on company-reported, not independently verified, results limits certainty.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problems
